A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon

M. Burress Welborn, Kimberly Van Zee, Paul D. Edwards, Jeffrey H. Pruitt, Atsushi Kaibara, J. N. Vauthey, Michael Rogy, William L. Castleman, Stephen F. Lowry, John S. Kenney, Dietrich Stüber, Urs Ettlin, Beat Wipf, Hansruedi Loetscher, Edward M. Copeland, Werner Lesslauer, Lyle L. Moldawer

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Tumor necrosis factor (TNF) is a potentially useful adjunct to anticancer therapies. However, the clinical utility of TNF has been limited by generalized toxicity and hypotension. Recently, studies have begun to dissect the individual proinflammatory and immunologic responses that result from TNF binding to its two cellular receptors, p55 and p75, in an attempt to develop TNF receptor agonists with reduced systemic toxicity. To evaluate a p75 receptor selective TNF mutant (p75TNF), TNF and p75TNF were administered to healthy anesthetized baboons. Intravenous infusion of the p75TNF produced none of the hemodynamic changes seen after the infusion of TNF. Infusion of p75TNF also failed to induce the plasma appearance of interleukins 6 and 8. However, p75TNF enhanced in vitro baboon thymocyte proliferation to concanavalin A, and infusion of p75TNF resulted in increased soluble p55 and p75 receptor plasma concentrations. Local skin necrosis and tissue neutrophil infiltration were seen after subcutaneous rejections of TNF and p55TNF. Subcutaneous injection of p75TNF did not result in skin necrosis but did result in a modest dermal infiltration of lymphocytes and macrophages. The findings suggest that p75TNF may stimulate T cell proliferation without the systemic and local toxicity seen with TNF.

Original languageEnglish (US)
Pages (from-to)165-171
Number of pages7
JournalJournal of Experimental Medicine
Volume184
Issue number1
DOIs
StatePublished - Jul 1 1996

Fingerprint

Papio
Tumor Necrosis Factor Receptors
Shock
Tumor Necrosis Factor-alpha
Cell Proliferation
Inflammation
T-Lymphocytes
Skin
Necrosis
Neutrophil Infiltration
Thymocytes
Subcutaneous Injections
Concanavalin A
In Vitro Techniques
human TNF protein
Interleukin-8
Intravenous Infusions
Hypotension
Interleukin-6
Hemodynamics

ASJC Scopus subject areas

  • Immunology

Cite this

A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. / Welborn, M. Burress; Van Zee, Kimberly; Edwards, Paul D.; Pruitt, Jeffrey H.; Kaibara, Atsushi; Vauthey, J. N.; Rogy, Michael; Castleman, William L.; Lowry, Stephen F.; Kenney, John S.; Stüber, Dietrich; Ettlin, Urs; Wipf, Beat; Loetscher, Hansruedi; Copeland, Edward M.; Lesslauer, Werner; Moldawer, Lyle L.

In: Journal of Experimental Medicine, Vol. 184, No. 1, 01.07.1996, p. 165-171.

Research output: Contribution to journalArticle

Welborn, MB, Van Zee, K, Edwards, PD, Pruitt, JH, Kaibara, A, Vauthey, JN, Rogy, M, Castleman, WL, Lowry, SF, Kenney, JS, Stüber, D, Ettlin, U, Wipf, B, Loetscher, H, Copeland, EM, Lesslauer, W & Moldawer, LL 1996, 'A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon', Journal of Experimental Medicine, vol. 184, no. 1, pp. 165-171. https://doi.org/10.1084/jem.184.1.165
Welborn, M. Burress ; Van Zee, Kimberly ; Edwards, Paul D. ; Pruitt, Jeffrey H. ; Kaibara, Atsushi ; Vauthey, J. N. ; Rogy, Michael ; Castleman, William L. ; Lowry, Stephen F. ; Kenney, John S. ; Stüber, Dietrich ; Ettlin, Urs ; Wipf, Beat ; Loetscher, Hansruedi ; Copeland, Edward M. ; Lesslauer, Werner ; Moldawer, Lyle L. / A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. In: Journal of Experimental Medicine. 1996 ; Vol. 184, No. 1. pp. 165-171.
@article{9b16423effd44c29af6a94124ec0895c,
title = "A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon",
abstract = "Tumor necrosis factor (TNF) is a potentially useful adjunct to anticancer therapies. However, the clinical utility of TNF has been limited by generalized toxicity and hypotension. Recently, studies have begun to dissect the individual proinflammatory and immunologic responses that result from TNF binding to its two cellular receptors, p55 and p75, in an attempt to develop TNF receptor agonists with reduced systemic toxicity. To evaluate a p75 receptor selective TNF mutant (p75TNF), TNF and p75TNF were administered to healthy anesthetized baboons. Intravenous infusion of the p75TNF produced none of the hemodynamic changes seen after the infusion of TNF. Infusion of p75TNF also failed to induce the plasma appearance of interleukins 6 and 8. However, p75TNF enhanced in vitro baboon thymocyte proliferation to concanavalin A, and infusion of p75TNF resulted in increased soluble p55 and p75 receptor plasma concentrations. Local skin necrosis and tissue neutrophil infiltration were seen after subcutaneous rejections of TNF and p55TNF. Subcutaneous injection of p75TNF did not result in skin necrosis but did result in a modest dermal infiltration of lymphocytes and macrophages. The findings suggest that p75TNF may stimulate T cell proliferation without the systemic and local toxicity seen with TNF.",
author = "Welborn, {M. Burress} and {Van Zee}, Kimberly and Edwards, {Paul D.} and Pruitt, {Jeffrey H.} and Atsushi Kaibara and Vauthey, {J. N.} and Michael Rogy and Castleman, {William L.} and Lowry, {Stephen F.} and Kenney, {John S.} and Dietrich St{\"u}ber and Urs Ettlin and Beat Wipf and Hansruedi Loetscher and Copeland, {Edward M.} and Werner Lesslauer and Moldawer, {Lyle L.}",
year = "1996",
month = "7",
day = "1",
doi = "10.1084/jem.184.1.165",
language = "English (US)",
volume = "184",
pages = "165--171",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon

AU - Welborn, M. Burress

AU - Van Zee, Kimberly

AU - Edwards, Paul D.

AU - Pruitt, Jeffrey H.

AU - Kaibara, Atsushi

AU - Vauthey, J. N.

AU - Rogy, Michael

AU - Castleman, William L.

AU - Lowry, Stephen F.

AU - Kenney, John S.

AU - Stüber, Dietrich

AU - Ettlin, Urs

AU - Wipf, Beat

AU - Loetscher, Hansruedi

AU - Copeland, Edward M.

AU - Lesslauer, Werner

AU - Moldawer, Lyle L.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Tumor necrosis factor (TNF) is a potentially useful adjunct to anticancer therapies. However, the clinical utility of TNF has been limited by generalized toxicity and hypotension. Recently, studies have begun to dissect the individual proinflammatory and immunologic responses that result from TNF binding to its two cellular receptors, p55 and p75, in an attempt to develop TNF receptor agonists with reduced systemic toxicity. To evaluate a p75 receptor selective TNF mutant (p75TNF), TNF and p75TNF were administered to healthy anesthetized baboons. Intravenous infusion of the p75TNF produced none of the hemodynamic changes seen after the infusion of TNF. Infusion of p75TNF also failed to induce the plasma appearance of interleukins 6 and 8. However, p75TNF enhanced in vitro baboon thymocyte proliferation to concanavalin A, and infusion of p75TNF resulted in increased soluble p55 and p75 receptor plasma concentrations. Local skin necrosis and tissue neutrophil infiltration were seen after subcutaneous rejections of TNF and p55TNF. Subcutaneous injection of p75TNF did not result in skin necrosis but did result in a modest dermal infiltration of lymphocytes and macrophages. The findings suggest that p75TNF may stimulate T cell proliferation without the systemic and local toxicity seen with TNF.

AB - Tumor necrosis factor (TNF) is a potentially useful adjunct to anticancer therapies. However, the clinical utility of TNF has been limited by generalized toxicity and hypotension. Recently, studies have begun to dissect the individual proinflammatory and immunologic responses that result from TNF binding to its two cellular receptors, p55 and p75, in an attempt to develop TNF receptor agonists with reduced systemic toxicity. To evaluate a p75 receptor selective TNF mutant (p75TNF), TNF and p75TNF were administered to healthy anesthetized baboons. Intravenous infusion of the p75TNF produced none of the hemodynamic changes seen after the infusion of TNF. Infusion of p75TNF also failed to induce the plasma appearance of interleukins 6 and 8. However, p75TNF enhanced in vitro baboon thymocyte proliferation to concanavalin A, and infusion of p75TNF resulted in increased soluble p55 and p75 receptor plasma concentrations. Local skin necrosis and tissue neutrophil infiltration were seen after subcutaneous rejections of TNF and p55TNF. Subcutaneous injection of p75TNF did not result in skin necrosis but did result in a modest dermal infiltration of lymphocytes and macrophages. The findings suggest that p75TNF may stimulate T cell proliferation without the systemic and local toxicity seen with TNF.

UR - http://www.scopus.com/inward/record.url?scp=8944220717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944220717&partnerID=8YFLogxK

U2 - 10.1084/jem.184.1.165

DO - 10.1084/jem.184.1.165

M3 - Article

VL - 184

SP - 165

EP - 171

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -